These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33801839)

  • 1. Antimicrobial Effects of Minocycline, Tigecycline, Ciprofloxacin, and Levofloxacin against
    Lin JN; Lai CH; Huang YH; Yang CH
    Antibiotics (Basel); 2021 Mar; 10(3):. PubMed ID: 33801839
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibiotic Combination to Effectively Postpone or Inhibit the In Vitro Induction and Selection of Levofloxacin-Resistant Mutants in
    Lee CC; Lai CH; Yang CH; Huang YH; Lin JN
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments.
    Wei C; Ni W; Cai X; Zhao J; Cui J
    PLoS One; 2016; 11(3):e0152132. PubMed ID: 26999818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining in vitro synergistic activities of tigecycline with several other antibiotics against Brucella melitensis using checkerboard and time-kill assays.
    Aliskan H; Can F; Demirbilek M; Colakoglu S; Kilic S; Arslan H
    J Chemother; 2009 Feb; 21(1):24-30. PubMed ID: 19297268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
    Scheetz MH; Qi C; Warren JR; Postelnick MJ; Zembower T; Obias A; Noskin GA
    Antimicrob Agents Chemother; 2007 May; 51(5):1621-6. PubMed ID: 17307973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis Isolated in Taiwan.
    Lin JN; Lai CH; Yang CH; Huang YH
    J Clin Med; 2018 Dec; 7(12):. PubMed ID: 30545016
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular characteristics and in vitro effects of antimicrobial combinations on planktonic and biofilm forms of Elizabethkingia anophelis.
    Tang HJ; Lin YT; Chen CC; Chen CW; Lu YC; Ko WC; Chen HJ; Su BA; Chang PC; Chuang YC; Lai CC
    J Antimicrob Chemother; 2021 Apr; 76(5):1205-1214. PubMed ID: 33532826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus.
    Tang HJ; Chen CC; Lai CC; Zhang CC; Weng TC; Chiu YH; Toh HS; Chiang SR; Yu WL; Ko WC; Chuang YC
    J Microbiol Immunol Infect; 2018 Feb; 51(1):76-81. PubMed ID: 27260781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoroquinolone resistance in carbapenem-resistant Elizabethkingia anophelis: phenotypic and genotypic characteristics of clinical isolates with topoisomerase mutations and comparative genomic analysis.
    Jian MJ; Cheng YH; Chung HY; Cheng YH; Yang HY; Hsu CS; Perng CL; Shang HS
    J Antimicrob Chemother; 2019 Jun; 74(6):1503-1510. PubMed ID: 30830171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro and In Vivo Antimicrobial Activities of Vancomycin and Rifampin against
    Lin IF; Lai CH; Lin SY; Lee CC; Lee NY; Liu PY; Yang CH; Huang YH; Lin JN
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069334
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates.
    Peck KR; Kim MJ; Choi JY; Kim HS; Kang CI; Cho YK; Park DW; Lee HJ; Lee MS; Ko KS
    J Med Microbiol; 2012 Mar; 61(Pt 3):353-360. PubMed ID: 22016557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo efficacy of minocycline-based therapy for Elizabethkingia anophelis and the impact of reduced minocycline susceptibility.
    Yang YS; Huang TW; Huang YC; Huang WC; Hsu SY; Wu HC; Chen FJ; Shang HS; Sytwu HK; Kuo SC
    Int J Antimicrob Agents; 2022; 60(5-6):106678. PubMed ID: 36184015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Ryan BM; Mazzucco CE; Lawrence LE; Ho H; Warr G; Barrett JF; Frosco M
    Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):27-34. PubMed ID: 11913498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biofilm formation and antibiotic sensitivity in
    Hu S; Lv Y; Xu H; Zheng B; Xiao Y
    Front Cell Infect Microbiol; 2022; 12():953780. PubMed ID: 35967866
    [No Abstract]   [Full Text] [Related]  

  • 15. Emerging infections in vulnerable hosts: Stenotrophomonas maltophilia and Elizabethkingia anophelis.
    Lee YL; Hsueh PR
    Curr Opin Infect Dis; 2023 Dec; 36(6):481-494. PubMed ID: 37548375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
    Visalli MA; Jacobs MR; Appelbaum PC
    Diagn Microbiol Infect Dis; 1997 Jul; 28(3):131-7. PubMed ID: 9294703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro efficacy of antimicrobial agents against high-inoculum or biofilm-embedded meticillin-resistant Staphylococcus aureus with vancomycin minimal inhibitory concentrations equal to 2 μg/mL (VA2-MRSA).
    Tang HJ; Chen CC; Ko WC; Yu WL; Chiang SR; Chuang YC
    Int J Antimicrob Agents; 2011 Jul; 38(1):46-51. PubMed ID: 21549575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Analysis of Gradient Diffusion and Disk Diffusion with Agar Dilution for Susceptibility Testing of
    Chiu CT; Lai CH; Huang YH; Yang CH; Lin JN
    Antibiotics (Basel); 2021 Apr; 10(4):. PubMed ID: 33923659
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator.
    Tang HJ; Ko WC; Chen CC; Chen PL; Toh HS; Weng TC; Yu WL; Chiang SR; Chuang YC
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2755-9. PubMed ID: 21402846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.